Drug intelligence / Profile preview

IBD101

Development stage: Preclinical
Lead developer: Shenzhen Zero-One Life Technology
Modality: Small Molecules
Administration: Oral

Overview

IBD101 is an orally administered small molecule drug candidate being developed by Shenzhen 01 Life Technology (01Life) for the treatment of inflammatory bowel disease (IBD). The drug is categorized as a new molecular entity (NME) within the company's pipeline, which focuses on small molecules derived from human commensal bacteria metabolites. As of early 2024, IBD101 is in the preclinical stage of development. While it is intended for the treatment of IBD, its specific molecular targets and detailed mechanism of action have not been publicly disclosed on the company's English-language pipeline documentation.

Beyond the preview

Go deeper on IBD101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBD101.

Explore the full profile